Consensus Insmed Incorporated

Stocks

INSM

US4576693075

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-11-11 EST			5-day change	1st Jan Change
120.75 ^USD	+1.05%		+9.77%	-30.62%

11-02	Mizuho Adjusts Price Target on Insmed to $158 From $154, Keeps Outperform Rating	MT
10-29	Insmed Q3 Net Loss Narrows; Revenue Rises	MT

Evolution of the Average Target: Insmed Incorporated

Evolution of the Target Price: Insmed Incorporated

Changes in Analyst Recommendations: Insmed Incorporated

b818e56e311dd04778.MankPk_wtBQKU0oZSk0nluU6VDWYRcgFvmrGPHqgRqI.et-WCgi0wC09IS92LhpQxIJwYQbCIKB05l-0ew6NFe1U7Z1NObXXRWclcg~0c3292b670cf59b09d4455ad493c5107

Analysts' recommendations: Insmed Incorporated

11-02	Mizuho Adjusts Price Target on Insmed to $158 From $154, Keeps Outperform Rating	MT
10-12	Insmed Shares Fall After Wolfe Research Downgrade	MT
10-12	Wolfe Research Downgrades Insmed to Peer Perform From Outperform	MT
08-25	Mizuho Adjusts Price Target on Insmed to $195 From $192, Keeps Outperform Rating	MT
08-07	Insmed Outlook Strengthens After Q2 Results, RBC Says	MT
07-21	BMO Capital Initiates Insmed at Outperform With $192 Price Target	MT
06-15	Mizuho Securities Adjusts Price Target on Insmed to $192 From $202, Maintains Outperform Rating	MT
06-05	Insmed Brinsupri Shows Strong Physician Conviction, Early Launch Momentum, RBC Says	MT
06-05	RBC Capital Adjusts Insmed Price Target to $195 From $205, Maintains Outperform Rating	MT
05-08	Insmed Stock Sell-off is Overdone as Underlying Metrics Appear Positive, RBC Says	MT
05-08	RBC Cuts Price Target on Insmed to $205 From $220, Keeps Outperform Rating	MT
04-14	Insmed Sees Favorable Physician Feedback on Brinsupri, RBC Capital Markets Says	MT
04-14	RBC Raises Price Target on Insmed to $216 From $212, Keeps Outperform Rating	MT
04-08	Mizuho Trims Price Target on Insmed to $202 From $206, Keeps Outperform Rating	MT
04-07	RBC Capital Adjusts Price Target on Insmed to $212 From $203, Maintains Outperform Rating	MT
03-31	UBS Adjusts Price Target on Insmed to $185 From $215, Maintains Buy Rating	MT
03-30	Insmed Sees Rising Physician Adoption of Brinsupri, Morgan Stanley Says	MT
03-30	Morgan Stanley Upgrades Insmed to Overweight From Equalweight, Raises Price Target to $212 From $166	MT
03-30	Analyst recommendations: AMD, Expedia, Instacart, Coinbase, Elf beauty…
03-24	Mizuho Lifts Price Target on Insmed to $206 From $204, Keeps Outperform Rating	MT
02-23	Mizuho Securities Cuts Insmed Price Target to $204 From $211, Maintains Outperform Rating	MT
02-20	Insmed Q4 Reinforces Confidence in Brinsupri Growth, RBC Says	MT
02-20	Insmed May Top Revenue Target for Bronchiectasis Drug Brinsupri, Morgan Stanley Says	MT
02-20	Morgan Stanley Lifts Price Target on Insmed to $166 From $162, Keeps Equalweight Rating	MT
01-28	Barclays Initiates Coverage on Insmed With Overweight Rating, $231 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	INSMED INCORPORATED					+62.51%
	WUXI APPTEC CO., LTD.					+34.62%
	ARGENX SE					+16.21%
	LONZA GROUP AG					+8.35%
	BEONE MEDICINES AG					+9.01%
	IQVIA HOLDINGS INC.					+13.35%
	REVOLUTION MEDICINES, INC.					+42.36%
	CELLTRION, INC.					+35.65%
	GENMAB A/S					+13.29%
	WUXI BIOLOGICS (CAYMAN) INC.					+21.4%
	Average					+25.67%
	Weighted average by Cap.					+23.82%